Funding for this research was provided by:
ImClone System LLC, a wholly owned subsidiary of Eli Lilly and Company
Received: 27 June 2018
Accepted: 9 December 2018
First Online: 27 December 2018
Ethics approval and consent to participate
: The study (NCT00913835) was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines, the Declaration of Helsinki, and local laws and regulations. The study was approved by the following ethical review boards: Medstar Research Institute-Georgetown University Oncology Institutional Review Board; King’s Hospital Research Ethics Committee-King’s College Hospital; South East London Rec 3-King’s College Hospital; London–Dulwich Charing Cross Hospital; Henry Ford Health System.Institutional Review Board; Indiana University-Purdue University Institutional Review Board; Dana Farber Cancer Institute Office for Human Research Studies; Dana Farber Cancer Institute Office for the Protection of Research Subjects; University of California–Irvine IRB; Chesapeake Research Review; Presbyterian Healthcare System Institutional Review Board; Hospital Clinico San Carlos, Servicio Farmacologia Clinica 1a planta Ala Norte–Ciudad Universitaria; Atlantic Health System, Institutional Review Board; University of Southern California IRB. All patients provided written informed consent.
: Not applicable.
: WPM, MG, and ACH report no conflicts related to this manuscript. RTP reports research funding and SABs within de minimis.PP, AS are employees of Eli Lilly and Company and own stock.RI was an employee of Eli Lilly and Company at the time of manuscript preparation. He is currently employed by Celgene Corporation.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.